U.S. drug giant Merck is paying $ 300 million in a deal possibly worth more than $ 5 billion to partner Eisai in an effort to boost its star cancer immunotherapy treatment Keytruda, which could match up well in a combination with Eisai's Lenvima. (fortune.com)
Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths. (fortune.com)
The FDA has approved a four - week dosing schedule for Bristol - Myers Squibb's cancer immunotherapy treatment Opdivo, doubling the current two - week schedule for a variety of cancers. (fortune.com)